A randomized, double-blind comparison of OROS(® )hydromorphone and controlled-release morphine for the control of chronic cancer pain

BACKGROUND: Long-acting opioid formulations are advocated for maintaining pain control in chronic cancer pain. OROS(® )hydromorphone is a sustained-release formulation of hydromorphone that requires dosing once daily to maintain therapeutic concentrations. The objective of this study was to demonstr...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanna, Magdi, Thipphawong, John
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644667/
https://www.ncbi.nlm.nih.gov/pubmed/18976472
http://dx.doi.org/10.1186/1472-684X-7-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2644667/
https://www.ncbi.nlm.nih.gov/pubmed/18976472
http://dx.doi.org/10.1186/1472-684X-7-17

Ejemplares similares